My Report Says a Mutation Is 'Actionable': — What Does That Mean?

This situation is more common than many families expect. A mutation may be actionable by NCCN or ESMO criteria — referencing a drug approved by the US FDA or EMA — but that same drug may not yet have CDSCO approval in India. Your oncologist can tell you whether the drug is available through expanded access, named-patient programmes, or an ongoing clinical trial in India. Do not import or purchase unapproved medicines independently — ask your team what legitimate access routes look like for your specific drug and situation.

Some targeted therapies are available in India at significantly lower prices than internationally, either as approved generics or through manufacturer access programmes. Your oncologist and the hospital's financial counselling team are the right starting point. Many manufacturers run named-patient or compassionate access schemes that your treating team can apply for on your behalf. It is worth asking before assuming that cost makes it impossible — indicative prices change over time as more drugs go off-patent or face generic competition.

This is called co-occurring mutation, and it complicates the picture. More than one actionable mutation does not always mean more than one matched drug can be used simultaneously — some combinations are contraindicated, and clinical data for combining two targeted drugs is limited for most cancer types. Your oncologist will use the full clinical picture, including which mutation is most likely to be the primary driver of your cancer's growth, to decide which to target first. This is a situation where discussion at a molecular tumour board often adds real value.

This happens regularly, and it is not a contradiction. For some cancer types and stages, clinical evidence shows that starting with chemotherapy — or combining it with the targeted drug — achieves better outcomes than targeted therapy alone. An actionable mutation tells you a drug option exists; the evidence for your specific cancer type and stage tells your oncologist when and whether to use it. If you are unsure why the sequence was chosen, asking your oncologist to explain the reasoning is a reasonable question at any appointment.

Resistance to targeted therapy is common and anticipated. When a drug stops working, your oncologist may recommend repeat molecular testing on new tissue or a liquid biopsy, because the cancer may have developed a secondary resistance mutation. That secondary mutation is sometimes itself actionable — meaning a different drug may be effective. This is why comprehensive testing at the point of progression is often recommended by NCCN and ESMO guidance, and why the actionable mutation conversation may happen more than once during your treatment.

Testing requires adequate tissue, and older or very small biopsy samples sometimes do not provide enough material. In that situation, your oncologist may recommend a repeat biopsy of an accessible tumour site, or a liquid biopsy, which looks for tumour DNA circulating in the blood. Liquid biopsy does not always detect every mutation that tissue testing would find, so your oncologist will tell you which mutations are reliably identified in blood for your cancer type. This is usually a solvable problem — it is worth raising rather than assuming that testing is no longer possible.